BeiGene is a global biotechnology company specializing in the discovery, development, and commercialization of innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Founded in 2010, the company has rapidly expanded its presence worldwide, with operations in the United States, China, and other international markets. BeiGene's mission is to improve the accessibility and affordability of cancer treatments through a science-first approach, focusing on producing high-quality therapies efficiently.

The company has developed a robust oncology pipeline addressing a significant portion of global cancer incidences, conducting over 140 clinical trials with more than 20,000 patients. Notable achievements include receiving regulatory approvals in over 70 markets for three internally developed medicines and establishing a state-of-the-art biologics manufacturing facility in Hopewell, New Jersey, to expand production capabilities. This facility is expected to employ hundreds of workers and support the company's broader expansion strategy to deliver innovative medicines to a global patient population.